Medical device corrosion testing is not one method but a family of electrochemical and immersion procedures matched to specific device questions. For small finished metallic implants, ASTM F2129 uses cyclic potentiodynamic polarization to assess susceptibility to localized corrosion [1]. For devices containing two dissimilar metals in electrical contact, ASTM F3044 evaluates the potential for galvanic corrosion [3]. For absorbable metals such as magnesium, iron and zinc alloys, ASTM F3268 provides in vitro degradation screening that is explicitly for material comparison rather than in vivo prediction [7]. The practical challenge is sequencing these methods correctly: material screening first, finished-device testing second, and supplementary nickel release or surface characterization only when acceptance criteria are not met [4]. This guide explains the named workflows, the technical decision points, the evidence limitations and a concrete evaluation example.
F2129: Cyclic Polarization for Small Finished Implants
ASTM F2129 assesses small metallic implant devices, or components, in their final form and finish using forward and reverse potentiodynamic polarization. The scope includes vascular stents, ureteral stents, filters, support segments of endovascular grafts, cardiac occluders, aneurysm or ligation clips, and staples [1]. The standard is intended for metals with relatively high corrosion resistance, and the upper device size limit is set by the electrical current delivery capability of the test apparatus [1]. Because forming and finishing steps can materially change corrosion resistance, material screening alone does not provide critical data about device performance [1].
The method is deliberately severe. ASTM states that conditions are designed to be sufficiently aggressive to cause breakdown and deterioration of the devices, and these conditions may not necessarily be encountered in vivo [2]. Results in artificial physiological electrolytes are useful for comparing device materials, designs or manufacturing processes, but the test does not account for the effects of cells and proteins on in vivo corrosion behavior [2]. For nitinol devices, FDA recommends pitting corrosion testing per F2129 for prolonged exposure and permanent contacting devices, performed after simulated assembly and implantation including compression, loading and deployment through an in vitro fixture [4].
F3044: Galvanic Couples and Dissimilar Metal Contact
ASTM F3044 covers galvanic corrosion tests to characterize the behavior of two dissimilar metals in electrical contact intended for use in the human body. The dissimilar metals may be on the same implantable device or on component parts of individual devices [3]. The standard addresses specimen selection, specimen preparation, test environment, method of exposure and result evaluation [3]. Devices and components are intended to be tested in their finished condition, with metallurgical and surface condition as close as possible to the finished implant [3].
The standard exists because general guidance such as ASTM G71 provides background but lacks the specificity needed for medical implants [3]. F3044 is designed to accommodate a wide variety of device shapes and sizes through multiple holding device configurations [3]. The standard also carries explicit safety cautions around mercury and mercury-containing products, noting that mercury vapor is hazardous to health and corrosive to materials, and that users must determine the legality of sales in their location [3]. This is a procedural standard for characterizing galvanic behavior, not a pass/fail clinical acceptance rule.
A Suggested Workflow for a Nitinol Stent with a Dissimilar Marker
As a suggested sequence, not a validated protocol, a manufacturer could first confirm that the nitinol stent meets F2129 acceptance criteria after simulated crimping and deployment through an in vitro fixture, following the FDA recommendation to test the finished device rather than raw material [4]. If the stent includes a radiopaque marker made of a dissimilar metal, a separate F3044 evaluation would characterize the galvanic couple between the marker and the stent body in a simulated physiological environment [3]. If F2129 results fall short of acceptance criteria, the next step would be in vitro nickel ion release testing in buffered solution for at least 60 days, preceded by a risk assessment that establishes acceptable nickel limits based on potential toxicological risks [6]. This sequence keeps each standard in its proper role: F2129 for localized corrosion susceptibility, F3044 for dissimilar metal contact, and nickel release testing as a conditional escalation rather than a default requirement.
F3268: Degradation Screening for Absorbable Metals
ASTM F3268 is a guide for in vitro degradation testing of absorbable metals, applicable to magnesium, iron and zinc-based metals and alloys [7]. The described tests are not considered representative of in vivo conditions and could provide a more rapid or slower degradation rate than the actual in vivo corrosion rate. The standard states plainly that the methods are for material comparison purposes only and are not a predictor or substitute for evaluation of in vivo degradation properties [7]. This limitation is central to interpreting any F3268 result.
The guide recognizes that degradation of absorbable metals is not linear, so evaluations must be adapted to reflect varying stages and rates of degradation. Relevant factors can include the amount or percentage of tissue coverage of the implanted device and the metabolic rate of surrounding tissue, which is not necessarily accompanied by a high perfusion rate [7]. The experimental approaches control the corrosion test environment through standardized conditions and physiologically relevant electrolyte fluids, and a standardized degradation control material is incorporated to allow comparison and normalization of results across laboratories [7].
Sequencing Corrosion Tests in a Regulatory Submission
FDA's nitinol guidance describes a corrosion testing paradigm that begins with ASTM F2129 pitting corrosion testing. If results meet pre-specified acceptance criteria and the device uses an established surface finish with good clinical history, such as electropolishing, chemical etch or mechanical polishing, further testing may not be warranted [4]. If F2129 results do not meet acceptance criteria, the flowchart moves to in vitro nickel ion release testing and a risk assessment [4]. This sequence prevents unnecessary testing while preserving a defined escalation path.
For intravascular stents, FDA recommends characterizing the corrosion potential of the as-manufactured, non-fatigued stent according to the currently recognized version of ASTM F2129 or an equivalent method [6]. When manufacturing changes that could impact surface finish are implemented, F2129 testing or surface characterization should be performed to demonstrate that the surface is not adversely altered [6]. For devices containing nickel-rich alloys, if corrosion resistance and passivation layer characterization results do not meet pre-specified acceptance criteria, FDA recommends quantifying nickel ion release over time in a buffered solution such as phosphate buffered saline at physiologic temperature and pH, with testing conducted for at least 60 days [6].
Interpreting Electrochemical Results
Electrochemical test interpretation depends on the form of corrosion being evaluated. General corrosion and associated metal ion release can be evaluated for corrosion current, and for surface-treated devices this current should closely represent the rate of metal ion release. Pitting corrosion susceptibility is reflected by the difference between breakdown potential and corrosion potential rather than by corrosion current alone [8]. There do not appear to be broadly accepted limits for metal ion release, which complicates acceptance criteria [8].
The relationship between test solution and in vivo behavior is not automatic. Various studies have indicated that simulated physiological solutions commonly used in electrochemical tests are satisfactory substitutes for blood and other physiological fluids, and that blood proteins and amino acids do not appear to adversely affect corrosion rate or localized corrosion susceptibility. However, some allowance for the effect of oxygen may be necessary when using results obtained in deaerated test solutions to assess localized corrosion susceptibility in vivo [8]. Fretting corrosion of stents has been evaluated using breakdown-to-corrosion potential differences, but the application of cyclic polarization testing to fatigue-cycled stents has yet to be adopted as a recognized approach for assessing the effect of fretting on stent corrosion resistance [8].
Sources & references
- F2129 Standard Test Method for Conducting Cyclic Potentiodynamic Polarization Measurements to Determine the Corrosion Susceptibility of Small Implant Devices · www.astm.org
- F2129 Standard Test Method for Conducting Cyclic Potentiodynamic Polarization Measurements to Determine the Corrosion Susceptibility of Small Implant Devices · www.astm.org
- F3044 Standard Test Method for Evaluating the Potential for Galvanic Corrosion for Medical Implants · store.astm.org
- Nitinol-Technical-Guidance July 9 2021 · www.fda.gov
- F3044 Standard Test Method for Evaluating the Potential for Galvanic Corrosion for Medical Implants · www.astm.org
- Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and Food and Drug Administration Staff · www.fda.gov
- F3268 Standard Guide for in vitro Degradation Testing of Absorbable Metals · store.astm.org
- The Use of Electrochemical Techniques to Evaluate the Corrosion Performance of Metallic Biomedical Materials and Devices: · medinstitute.com